

# The Modern Laboratory: Single Use technologies vs traditional solutions

A discussion on the advantages, disadvantages and comparative costs

## Introduction

Every development process in an innovative biotechnology or biopharmaceutical plant has an identical goal: to bring a new bio-based product to market while taking into account acceptable costs and maximizing profits. One of the biggest sources of the cost of goods is the production process itself, and therefore also the type of technology used in this process. Traditional bioproduction plants rely on stainless steel (SS) fermenters with large capacities (20000L or more) and related downstream processing equipment. In the mid-2000s,



50L SU CellMaker bioreactors in a bacteriophage production lab

the dominant status of the reusable bioprocess technologies encountered competition from the first single use (SU) fermenters. At this point, a dilemma emerged as to which type of technology to choose, and which one would be the most efficient and suitable for a given bioprocess. Although disposable fermentation systems are still very limited in scale compared to stainless steel systems (the largest disposable systems currently reach around 5,000L), they are more often used as equipment in innovative biotechnology labs than difficult to use and expensive to upkeep SS systems. As a representative of a manufacturer of SU systems, the first question I encounter most often is how to compare the costs of SU systems to more traditional reusable solutions. Undoubtedly, anyone considering switching to a SU system immediately notices the cost of consumables. Mostly, they indicate that these costs are very high, and fermentation in a steel bioreactor requires virtually no operating costs. They also say that the disposable materials generate huge amounts of waste. This reaction is perfectly logical and understandable; however, the reality is surprisingly much more complex.

## Advantages of Single-Use

Compared to SS solutions, the main advantage of the SU technology is the absence of cleaning and sterilization in place (CIP/SIP) normally required between processes in each of the SS devices. This routine activity takes a long time and requires the instruments to be turned off, frequently for several days at a time and requires the system to be certified for sterility prior to being used again. Switching to a SU system, CIP sterility validation is transferred from the operator to the equipment

manufacturer. In addition, SU technologies allow for a much greater scope for adapting the laboratory to conduct various bioprocesses, excluding the danger of cross-contamination. For example, a bioprocessing laboratory outfitted with reusable equipment is usually dedicated to only one type of bioproduct, therefore, the production of various preparations requires construction of multiple production lines. On the other hand, using SU technologies we can completely replace all


components of the production line, which come in contact with the process, with new ones, and thus completely separate the processes despite using the same equipment. By avoiding the cleaning of

equipment between batches, we also save on staff work time, who can focus on the production instead of equipment maintenance.


## Costs Analysis

The costs and profits analysis of SS and SU technologies is also very interesting. The highest costs of SS technology are the cost of purchase and installation, followed by the cost of CIP/SIP<sup>1</sup>, including labour time and costs. SU solutions have significantly lower capital costs, up to 40%<sup>2,3</sup>, and a much faster lead time for delivery of capital equipment, which allows for more time to make the final decision on which particular SU solution will be used in the newly created laboratory or processing plant. In addition, SU systems reduce operating costs by up to 20% and employee costs by a further 10%<sup>4</sup>. Of course, these costs are partly offset by high consumables prices, however, on balance the costs of the energy required to maintain a SS system outstrips the consumable costs of SU.

The potential profits should also be considered in the above calculations, as well as costs of goods. For example, according to a recent study, the profits from the production of 2000L of monoclonal antibody suspension in a SS system in comparison to a SU system, in which not only the bioreactor system was replaced with a SU solution but also the centrifuges were replaced by filtration systems, the SU system generated 91kg of bioproduct at a total cost of 70 Euro/g. The SS system, on the other hand, yielded only 87kg of product with a cost of 102 Euro/g<sup>2</sup>. According to the authors of this study, the main sources of difference in the cost of goods are the product losses during downstream processing and the maintenance costs of the reusable equipment, including chemicals and deionized water used for CIP/SIP.



Proportional comparison of costs of 3000kg of product at production scale of bioproduct



using single use or reusable technologies per year. Based on Mahal et al. 2021

## Environmental Costs

In addition to financial costs, environmental costs are also inevitable in any bioprocess. SU technologies generate large amounts of plastic waste. Their presence is very visible, and the sizes can be overwhelming. However, a well-managed bioprocess plant can use the services of incineration plants, where some of the energy used for the production of consumables can be recovered as heat from incineration of the waste material<sup>5</sup>. In addition, the cost of energy, highly toxic

chemicals necessary for CIP/SIP processes, their disposal and production of deionized water necessary for cleaning of the machinery, is often hidden in indirect costs. These can amount to even 13% of the total production costs on a scale of 3000kg of the product per year or even more at smaller production scales. In comparison, the cost of combustion of the SU consumables can be significantly lower than the CIP/SIP costs<sup>1,3,5</sup>.

## Conclusions

In summary, the answer to the question of which technology to choose, reusable or disposable, is not a straightforward one. Such a decision should be based on the type of bioprocess being performed, the certification requirements and the needs of the bioprocessing plant. When choosing an SU technology provider, we choose not only a contractor, but also a partner for a

long period. The SS solution provider, similarly, should be able to guarantee long-term service of the equipment. Undoubtedly, however, SU technologies are more flexible and adaptable, and particularly useful where the ability to quickly switch to new requirements is crucial, and your equipment is used for a wide range of applications both upstream and downstream.

## Author



**Dr Adam Ostrowski**

### **Technical Application Lead at Cellexus**

Adam is a molecular microbiologist & an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions & achieve the best possible results using our technology. Adam also helps develop new applications & technical solutions for our airlift-mixed single-use bioreactor range & delivers custom requirements & improvements as requested by our customers. Before joining Cellexus, Adam worked in bacteriophage treatment development for plant crop protection & during his academic career has studied Type VI Secretion system and functional proteins in bacterial communities.

## References

1. Mahal, H., Branton, H. & Farid, S. S. End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies. *Biotechnol. Bioeng.* bit.27774 (2021) oi:10.1002/bit.27774.
2. Gupta, P., Monge, M., Boulais, A., Chopra, N. & Hutchinson, N. Single-Use Process Platforms for Responsive and Cost-Effective Manufacturing. in *Single-Use Technology in Biopharmaceutical Manufacture 201-210* (Wiley, 2019). doi:10.1002/9781119477891.ch16.
3. Guldager, N. Cost advantages of single use technologies. *Pharm. Technol.* 34, 26-31 (2010).
4. Lütke-Eversloh, T. & Rogge, P. Biopharmaceutical manufacturing in single-use bioreactors current status and challenges from a CDMO perspective . *Pharm. Ind.* 80, 281-284 (2018).
5. Flanagan, W. et al. An Environmental Lifecycle Assessment of Single-Use and Conventional Process Technology: Comprehensive Environmental Impacts. *BioPharm Int.* 27, 40-46 (2014).

## Contact details

Cellexus International Limited  
6 Riverside Court, Mayo Avenue  
Dundee, DD2 1XD, UK

Email: [enquiries@cellexus.com](mailto:enquiries@cellexus.com)  
Office: +44 (0) 1382 666357  
[www.cellexus.com](http://www.cellexus.com)

Contact us for more information or  
to request a demonstration.